Analyst Raises Personalis Price Target to $17 on Heightened Takeover Prospects and Maintains Buy Rating

Personalis, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Michael Matson from Needham assigned a Buy rating on the stock and has a $17.00 price target.

TipRanks Welcomes a New ETF – NYSE:RANK

• TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE.
• RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.

Michael Matson has given his Buy rating due to a combination of factors, most notably the reported takeover interest in Personalis from Merck and at least two other potential acquirers. He highlights that both Merck and Tempus AI already hold sizable ownership stakes in Personalis, which reinforces the strategic appeal of the company and supports the likelihood that Tempus AI is among the additional interested parties.

Matson also points out that Personalis shares have significantly outperformed the broader market recently, a move he believes is largely driven by investors anticipating a possible acquisition. Based on this elevated probability of a transaction and the current trading level around $15.58, he revises his price target upward from $12 to $17, reflecting limited additional upside but still enough potential value creation to justify maintaining a Buy recommendation.

Matson covers the Healthcare sector, focusing on stocks such as Artivion, Boston Scientific, and Veracyte. According to TipRanks, Matson has an average return of 5.6% and a 49.00% success rate on recommended stocks.

In another report released on July 15, TD Cowen also maintained a Buy rating on the stock with a $18.00 price target.